This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ZBH or ESLOY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ZBH vs. ESLOY: Which Stock Is the Better Value Option?
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Should You Add Zimmer Biomet Stock to Your Portfolio Now?
by Zacks Equity Research
ZBH rides on knee innovation and robotics growth, but debt and macro pressures challenge its upside potential.
ZBH vs. ESLOY: Which Stock Is the Better Value Option?
by Zacks Equity Research
ZBH vs. ESLOY: Which Stock Is the Better Value Option?
Stryker's Robotics and Global Gains Offset by Macro Concerns
by Zacks Equity Research
SYK posted strong Q2 growth driven by Mako robotics and global demand, but inflation, FX and competitive pressures temper near-term upside.
Top Analyst Reports for Netflix, Mastercard & Shell
by Mark Vickery
Netflix's ad tier drives over 55% of new sign-ups as its content slate and global strategy fuel a bold revenue growth target for 2030.
Here's Why Zimmer Biomet (ZBH) is a Strong Momentum Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ISRG's Post-Earnings Slide: Margin Worries Overshadow Growth Story
by Indrajit Bandyopadhyay
Intuitive Surgical's Q2 revenues and procedure gains look good, but tariffs, cost inflation, and margin pressure spur a post-earnings selloff.
ZBH Stock Gains On Q2 Earnings and Revenue Beat, '25 EPS View Up
by Zacks Equity Research
Zimmer Biomet gains as Q2 earnings and revenues top estimates; full-year EPS guidance raised on strong segment growth.
Zimmer (ZBH) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Zimmer (ZBH) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zimmer Biomet (ZBH) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of +4.55% and +1.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Exploring Analyst Estimates for Zimmer (ZBH) Q2 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
ISRG's Ion Platform Sees Uptick in Utilization, Eyes Efficiency
by Indrajit Bandyopadhyay
Intuitive Surgical's Ion platform posted 52% procedure growth in Q2, but rising system utilization and workflow efficiency now drive its profitability focus.
Zimmer Biomet to Report Q2 Earnings: Here's What to Expect
by Zacks Equity Research
ZBH's Q2 results may show strength in Hips, Knees, and S.E.T. despite a projected year-over-year earnings dip.
Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Canopy Growth (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Zimmer Biomet (ZBH) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside?
by Indrajit Bandyopadhyay
ISRG's Q2 procedure growth hits 17%, but continuation of EPS growth hinges on easing margin pressure from FX and da Vinci 5 adoption.
ZBH Stock Set to Benefit From New Monogram Technologies Buyout Deal
by Zacks Equity Research
Zimmer Biomet eyes long-term gains with the $177M Monogram buyout, aiming to expand its robotic knee surgery offerings by 2027.
ISRG Expands Installed Base, But Is Utilization Keeping Pace?
by Indrajit Bandyopadhyay
Intuitive Surgical's installed base tops 10,000, but flat utilization growth raises questions about ROI and system productivity.
ISRG Margin Outlook Dips on Tariffs, Demand Signals Stay Strong
by Harshit Gupta
Intuitive Surgical trims margin outlook on tariff headwinds, but strong procedure growth and financial resilience bolster its long-term case.